BioCentury | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

...fibrillary acidic protein (GFAP) in astrocytes. Down-regulated genes included synaptosomal-associated protein 25 (SNAP25) in oligodendrocytes, RAR-related orphan receptor A (RORA)...
...protein (GFAP) Leucine rich repeat and Ig domain containing 1 (LINGO1) Potassium voltage-gated channel interacting protein 1 (KCNIP1) RAR-related orphan receptor A (RORA) Synaptosomal-associated...
BioCentury | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest the short-chain fatty acid pentanoate could help treat MS. In primary mouse T helper type 17 (Th17) cells pentanoate increased expression of...
BioCentury | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BioCentury | Feb 14, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Autoimmune disease

...CH25H-RORA axis could help treat osteoarthritis. In patients, mRNA and protein levels of CH25H and RORA...
...with normal CH25H expression. In one of the models, systemic knockout of RORA or an RORA...
...identifying and testing CH25H and RORA inhibitors in the models. TARGET/MARKER/PATHWAY: Cholesterol 25 hydroxylase (CH25H); RAR-related orphan receptor A (RORA)...
BioCentury | Nov 13, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture, mouse, rat and dog studies identified a RORγT inverse agonist that could help treat inflammation. Chemical synthesis and screening of a subset of Pfizer Inc.’s small compound library in a HEK-cell...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro and mouse studies identified a RORγT inverse agonist that could help treat delayed-type hypersensitivity (DTH)-associated inflammation. Fragment-based screening, chemical synthesis of phenyl-acetamide-based analogs of the screening hit, and in vitro and...
BioCentury | Apr 30, 2018
Company News

Allergan drops RORgammaT inhibitor for psoriasis

Allergan plc (NYSE:AGN) terminated development of VTP-43742 to treat psoriasis due to safety signals in a Phase II study, EVP and Chief R&D Officer C. David Nicholson said on the company's 1Q18 earnings call. The...
BioCentury | Apr 20, 2018
Clinical News

Lycera reports Phase I data for solid tumor candidate LYC-55716

Lycera Corp. (Ann Arbor, Mich.) reported data from 26 evaluable patients with relapsed or refractory solid tumors in the Phase I portion of the Phase I/IIa ARGON trial showing that oral LYC-55716 led to one...
Items per page:
1 - 10 of 89